ライフサイエンスコーパス: nucleotide binding

1 er the nucleotide phosphates) that accompany nucleotide binding.

2 alized, ordered, hydrated, and available for nucleotide binding.

3 n this conformation may deleteriously affect nucleotide binding.

4 NA and the downregulation of Histidine triad NucleoTide-binding 1 (HNT1) mRNA.

5 g a HEPN (Higher Eukaryotes and Prokaryotes, Nucleotide binding) active site.

6 we found that the binding of NSm affects the nucleotide binding activity of the NB-ARC-LRR in vitro,

7 ogy analysis all strongly support defects in nucleotide-binding activity.

8 nd their homologs that represent the NB-ARC (nucleotide-binding adaptor shared by APAF-1, certain R g

9 putative adenylyl cyclase domain fused to a nucleotide-binding adaptor shared by apoptotic protease-

10 site rearrangements that lead to a decreased nucleotide binding affinity and incorporation rate.

11 role similar to their K-Ras counterparts in nucleotide binding and activation.

12 s at the active site that promote productive nucleotide binding and couple with changes at the activa

13 inhibition, both in directly contributing to nucleotide binding and in stabilising the nucleotide-bou

14 f enzyme conformational changes that monitor nucleotide binding and incorporation.

15 stopped-flow kinetic measurements of correct nucleotide binding and incorporation.

16 amyloid signaling pathways involving fungal nucleotide binding and oligomerization domain (NOD)-like

17 and negative cooperativity for substrate and nucleotide binding and product release.

18 imity to the bound ATP, suggesting a role in nucleotide binding and/or hydrolysis.

19 chemical modifications that are monitored by nucleotide-binding and leucine-rich repeat (NLR) immune

20 Disease resistance genes encoding nucleotide-binding and leucine-rich repeat (NLR) intrace

21 Nucleotide-binding and leucine-rich repeat immune recept

22 Nucleotide-binding and leucine-rich repeat-containing re

23 of transposable elements in the expansion of nucleotide-binding and leucine-rich-repeat proteins (NLR

24 Sse1sbd retains nucleotide-binding and nucleotide exchange activities wh

25 Nucleotide-binding and oligomerization domain (NOD)-like

26 urs at the site of communication between the nucleotide-binding and substrate-binding domains of Hsp7

27 Large structural changes within the nucleotide-binding and transmembrane regions push conser

28 Nucleotide binding- and leucine-rich repeat domains of N

29 nian ratchet or power stroke models invoking nucleotide binding as the driving force.

30 trate without perturbing the equilibrium for nucleotide binding at physiological Mg(2+) concentration

31 at increases channel activity did not affect nucleotide binding, but greatly perturbed the ability of

32 M) of the Walker A motif beyond the motif's nucleotide-binding characteristic.

33 d dimer but the network hub shifted from the nucleotide binding cleft to the captured peptide.

34 e PEAK1 kinase-like domain contains a closed nucleotide-binding cleft that in this conformation may d

35 y caused by the absence of the second cyclic nucleotide binding (CNB) domain and the J-domain in one

36 ne binding required the high-affinity cyclic nucleotide-binding (CNB) and Ras association domains, bu

37 Cyclic nucleotide-binding (CNB) domains allosterically regulate

38 ains and is in an open configuration that is nucleotide binding-competent.

39 ve to 8-oxoG bypass is due to an alternative nucleotide binding conformation in the precatalytic tern

40 the risk of N-acetylation and identify where nucleotide binding could enhance N-acylation in vivo.

41 We also found that upon nucleotide binding, CrSEPT formed dimers that were stabi

42 that engagement of the MukB ATPase heads on nucleotide binding directs the formation of dimers of he

43 main of MANF selectively associates with the nucleotide binding domain (NBD) of ADP-bound BiP.

44 ranslocated bacterial products are sensed by nucleotide binding domain and leucine-rich repeat-contai

45 eral surface-exposed proline residues in the nucleotide binding domain and linker of Arabidopsis ABCB

46 tion in the catalytic site of the C-terminal nucleotide binding domain restored proper protein traffi

47 MlaB, a STAS domain protein, binds the ABC nucleotide binding domain, MlaF, and is required for its

48 us region of DnaK, involving lobe IIA of the nucleotide binding domain, the inter-domain linker, and

49 missense, deletion and nonsense mutations in nucleotide binding domain-2 (NBD2), including W1282X, N1

50 the transmembrane domain and the C-terminal nucleotide binding domain.

51 nds that interact with the regulatory cyclic nucleotide-binding domain (CNB) of the cAMP sensor, EPAC

52 ting is mediated by the intracellular cyclic nucleotide-binding domain (CNBD) connected to the pore-f

53 Binding of cAMP to the cyclic nucleotide-binding domain (CNBD) facilitates channel ope

54 n two well-structured domains: an N-terminal nucleotide-binding domain (NBD) and a C-terminal substra

55 NLRP6 is a sensor protein in the nucleotide-binding domain (NBD) and leucine-rich repeat

56 te-controllable docking and undocking of its nucleotide-binding domain (NBD) and substrate-binding do

57 docked model predicted that a region in the nucleotide-binding domain (NBD) of DnaK interacted with

58 e to species-selectivity, we investigate the nucleotide-binding domain (NBD) of Hsp90 from the most c

59 ponent of immunoregulation and a subgroup of nucleotide-binding domain (NBD), leucine-rich repeat (LR

60 ydrate-binding domain (CBD) that extends its nucleotide-binding domain (NBD).

61 of phenylalanine 508 (F508del) in the first nucleotide-binding domain (NBD1) of the cystic fibrosis

62 e-causing mutations located within the first nucleotide-binding domain (NBD1) of the cystic fibrosis

63 ointed critical N-terminal domain (NTD), NTD-nucleotide-binding domain 1 (NBD1) linker, NBD1, and mid

64 se cycle is rate-limited by ADP release from nucleotide-binding domain 1 (NBD1).

65 e reproduced in vitro using purified F508del nucleotide-binding domain 1 and SUMOylation reaction com

66 and persistence of the H3 helix in DeltaF508 nucleotide-binding domain 1.

67 ic assembly of the channel; ATP binds at the nucleotide-binding domain and inhibits channel activity.

68 NLRC4 [nucleotide-binding domain and leucine-rich repeat (NLR)

69 oehn et al investigate how activation of the nucleotide-binding domain and leucine-rich repeat (NLR)

70 Nucleotide-binding domain and leucine-rich repeat (NLR)-

71 urrently evolved at the DANGEROUS MIX2 (DM2) nucleotide-binding domain and leucine-rich repeat (NLR)-

72 nSeq) was developed to accelerate mapping of nucleotide-binding domain and leucine-rich repeat contai

73 MHC class I transactivator (CITA), NLRC5 [nucleotide-binding domain and leucine-rich repeats conta

74 tural element in synergy with the HCN cyclic nucleotide-binding domain and specific interactions near

75 the nucleotide-binding domain and substrate-binding domain)

76 In this report, we found that the cyclic nucleotide-binding domain and the C terminus of the HCN

77 The N-terminal nucleotide-binding domain and the C-terminal coiled-coil

78 lex by constraining the distance between the nucleotide-binding domain and the membrane surface.

79 rmation of a conserved proline in the cyclic nucleotide-binding domain determines the activation kine

80 inding of ATP and thereby impair ATP-induced nucleotide-binding domain dimerization and ABCB4 functio

81 YcjX features a Walker-type nucleotide-binding domain indicating that YcjX might fun

82 terminal linker connecting S6 and the cyclic-nucleotide-binding domain interacts directly with both t

83 Nucleotide-binding domain leucine-rich repeat (NLR) prot

84 In this study, we explore the role of nucleotide-binding domain leucine-rich repeat containing

85 In this study, we explore the role of the nucleotide-binding domain leucine-rich repeat containing

86 ivate homozygous mutation in NLRP1, encoding Nucleotide-Binding Domain Leucine-Rich Repeat Family Pyr

87 Pm5e encodes a nucleotide-binding domain leucine-rich-repeat-containing

88 ent of MBD1-3 was found to interact with the nucleotide-binding domain of ATP7B, thus physically coup

89 The nucleotide-binding domain of NLRP12 interacts with the u

90 We show that TRIP8b binds the HCN cyclic nucleotide-binding domain through a 37-residue domain an

91 vated type I interferon production, and NLR (nucleotide-binding domain, leucine repeat domain-contain

92 in-1beta (IL-1beta), interleukin-18 (IL-18), nucleotide-binding domain, leucine rich family (NLR) pyr

93 e leukocytes to produce MPs and activate the nucleotide-binding domain, leucine-rich repeat pyrin dom

94 Here, we show that nucleotide-binding domain, leucine-rich repeat, and pyri

95 In mice, specific nucleotide-binding domain, leucine-rich repeat-containin

96 sis inhibitory proteins (NAIPs) activate the nucleotide-binding domain, leucine-rich repeat-containin

97 bsiella hemolysin gene; TNF-alpha; IFN-beta; nucleotide-binding domain, leucine-rich-containing famil

98 tion of EGFR, protease-activated receptor 2, nucleotide-binding domain, leucine-rich-containing famil

99 tion of EGFR, protease-activated receptor 2, nucleotide-binding domain, leucine-rich-containing famil

100 ress immunity; however, the plant can evolve nucleotide-binding domain-leucine-rich repeat domain-con

101 characterized by alternative splicing in the nucleotide-binding domain.

102 regulated by binding of ATP/ADP to mtHsp70's nucleotide-binding domain.

103 ctivity and binds ATP only in its N-terminal nucleotide-binding domain.

104 adenosine triphosphate turnover in the first nucleotide-binding domain.

105 The nucleotide-binding-domain (NBD)-and leucine-rich repeat

106 NLRX1 is unique among the nucleotide-binding-domain and leucine-rich-repeat (NLR)

107 e transport cycle is the dissociation of the nucleotide-binding-domain dimer, while ATP hydrolysis pe

108 s undergone at the critical interfaces where nucleotide binding domains (NBDs) contact intracellular

109 Two AAA+ nucleotide binding domains (NBDs) power polypeptide tran

110 membrane by coupling ATP-driven movements of nucleotide binding domains (NBDs) to the transmembrane d

111 uggesting intact ion permeation pathways and nucleotide binding domains (NBDs), albeit with reduced o

112 of a dysfunctional ATP-binding site 2 in the nucleotide binding domains (NBDs).

113 e second ATP binding site (or site 2) in the nucleotide binding domains (NBDs).

114 The interface between its two cytosolic nucleotide binding domains and coupling helices conferre

115 d in conserved residues of either of the two nucleotide binding domains and determined the effect on

116 l inward-facing conformation whereby the two nucleotide binding domains are misaligned along a two-fo

117 s reveals how reversible dimerization of the nucleotide binding domains drives opening and closing of

118 The nucleotide binding domains form a closed conformation co

119 Here we show that DNA bricks with longer, 13-nucleotide binding domains make it possible to self-asse

120 etween multiple binding events in the cyclic nucleotide binding domains of HCN pacemaker channel.

121 ngin domains heterodimerize and contact both nucleotide binding domains of the Rag heterodimer, while

122 2 nucleotides long, consisting of four eight-nucleotide binding domains.

123 ibitory segment (AIS), four predicted cyclic nucleotide-binding domains (CNBs), and a kinase domain (

124 disengaged from its inhibitory position; the nucleotide-binding domains (NBDs) form a "head-to-tail"

125 r-bound ABCB1 sites are amplified toward the nucleotide-binding domains (NBDs), revealing how the pla

126 tional states with minimal separation of the nucleotide-binding domains in the inward-facing conforma

127 Point mutations in the two nucleotide-binding domains of ABCF3 affected sphingosine

128 ins forming a translocation pathway, and two nucleotide-binding domains that hydrolyze ATP.

129 p connect the transmembrane domains with its nucleotide-binding domains, and several residues in thes

130 protein, in the drug-binding pocket and the nucleotide-binding domains.

131 g suggested unequal contributions by the two nucleotide-binding domains.

132 in part, at ATP-binding site 1 formed by the nucleotide-binding domains.

133 idative stress does not significantly impact nucleotide binding equilibria, but does stimulate a 2-fo

134 onic currents suggests a model in which each nucleotide binding event to NBS2 of SUR1 is independent

135 calization of these events revealed that SRX-nucleotide-binding events are fivefold more frequent in

136 cts of RRAS2 biochemical behavior, including nucleotide binding, GTP hydrolysis, and interaction with

137 Although cyclic nucleotide binding has been shown to promote CNG and HCN

138 ber of the higher eukaryotes and prokaryotes nucleotide-binding (HEPN) domain-containing nuclease fam

139 by the two Higher Eukaryotes and Prokaryotes Nucleotide-binding (HEPN) domains, is required for degra

140 Nucleotide-binding, hydrolysis, and exchange reactions d

141 al methods, we have investigated the role of nucleotide binding in UvrA's kinetic cycle.

142 eport results from assays for solution-based nucleotide binding, intrinsic and GTPase-activating prot

143 alysis afforded thermodynamic parameters for nucleotide binding (Kd , DeltaG, DeltaH, and DeltaS at 3

144 Plant intracellular nucleotide binding leucine-rich repeat (NLR) immune rece

145 Five nucleotide binding leucine-rich repeat contigs distingui

146 Plant innate immunity relies on nucleotide binding leucine-rich repeat receptors (NLRs)

147 Here we identify epigenetic regulation of nucleotide-binding leucine rich repeat or Nod-Like Recep

148 Plant nucleotide-binding leucine-rich repeat (NLR) disease res

149 Wolffia has also lost most of the conserved nucleotide-binding leucine-rich repeat (NLR) genes that

150 Plant nucleotide-binding leucine-rich repeat (NLR) immune rece

151 Nucleotide-binding leucine-rich repeat (NLR) immune rece

152 Plant nucleotide-binding leucine-rich repeat (NLR) immune rece

153 gers cell death and autoimmunity through the nucleotide-binding leucine-rich repeat (NLR) protein SUM

154 to identify Recognition of XopQ 1 (Roq1), a nucleotide-binding leucine-rich repeat (NLR) protein wit

155 ACQOS is identical to VICTR, encoding a nucleotide-binding leucine-rich repeat (NLR) protein(3).

156 RPS5, a nucleotide-binding leucine-rich repeat (NLR) protein, is

157 Plant nucleotide-binding leucine-rich repeat (NLR) proteins en

158 Nucleotide-binding leucine-rich repeat (NLR) proteins pl

159 ts, disease resistance is often conferred by nucleotide-binding leucine-rich repeat (NLR) proteins, i

160 hed with stress response proteins, including nucleotide-binding leucine-rich repeat immune receptors,

161 d that narrowed the Ptr1 candidates to eight nucleotide-binding leucine-rich repeat protein (NLR)-enc

162 s, including a detailed multi-genome-derived nucleotide-binding leucine-rich repeat protein repertoir

163 luding two linked genes encoding coiled-coil nucleotide-binding leucine-rich repeat proteins designat

164 Nucleotide-binding leucine-rich repeat receptors (NLRs)

165 etect pathogen infection using intracellular nucleotide-binding leucine-rich repeat receptors (NLRs)

166 -function mutations in the gene encoding the nucleotide binding, leucine-rich repeat (NLR) protein Nb

167 in the translation of TIR domain-containing, nucleotide binding, leucine-rich repeat (TNL) immune rec

168 ssion by at least one of four genes encoding nucleotide-binding, leucine-rich repeat (NLR) immune rec

169 A nucleotide-binding, leucine-rich repeat (NLR) immune rec

170 ogens, and most R genes encode intracellular nucleotide-binding, leucine-rich repeat (NLR) proteins.

171 Nucleotide-binding, leucine-rich repeat containing X1 (N

172 The NLRs or NBS-LRRs (nucleotide-binding, leucine-rich-repeat) form the larges

173 plants, on top of existing phytohormone and nucleotide-binding-leucine-rich-repeat (NLR) networks, t

174 Plant nucleotide binding/leucine-rich repeat (NLR) immune rece

175 contains the Walker A sequence, a well-known nucleotide-binding motif.

176 Its motor domain contains conserved nucleotide binding motifs, but is divergent in sequence

177 Finally, we demonstrate that the nucleotide-binding motifs of the predicted atypical kina

178 We show that the Grp94 N-terminal nucleotide-binding N domain is responsible for accelerat

179 (TIR) or coiled-coil (CC) domain, a central nucleotide-binding (NB) domain, and a C-terminal leucine

180 Plant nucleotide-binding (NB) leucine-rich repeat (LRR) recept

181 NLR (nucleotide-binding [NB] leucine-rich repeat [LRR] recept

182 In the present study, we identified nucleotide binding oligomerization domain (Nod)-like rec

183 *Nucleotide binding oligomerization domain (Nod)-like rec

184 of genes encoded for components of the TLR, nucleotide binding oligomerization domain-like receptor,

185 ptides) activate innate immune cells through nucleotide-binding oligomerization domain (NOD) 1 and/or

186 bacterial sensors, it was proposed that the nucleotide-binding oligomerization domain (NOD) proteins

187 , termed the inflammasome, by members of the nucleotide-binding oligomerization domain (Nod), leucine

188 ation of immune response pathways, including nucleotide-binding oligomerization domain (NOD)-, Toll-,

189 Nucleotide-binding oligomerization domain (Nod)-containi

190 we highlight recent advances on the roles of nucleotide-binding oligomerization domain (NOD)-like rec

191 The nucleotide-binding oligomerization domain (NOD)-like rec

192 yrin domain containing 1 (NLRP1), NLRP3, and nucleotide-binding oligomerization domain (NOD)-like rec

193 Nucleotide-binding oligomerization domain 1 (NOD1) is an

194 de (MDP) adjuvant, which activates cytosolic nucleotide-binding oligomerization domain 2 (NOD2).

195 lasmatic pattern recognition receptor, NOD2 (nucleotide-binding oligomerization domain 2), belongs to

196 We demonstrate that both TNF-R and nucleotide-binding oligomerization domain stimulation pr

197 Nucleotide-binding oligomerization domain, leucine rich

198 The inflammasome proteins nucleotide-binding oligomerization domain, leucine rich

199 ncentrations of 25 nmol/L or greater induced nucleotide-binding oligomerization domain, leucine-rich

200 , including IL-1 receptor (IL-1R) family and nucleotide-binding oligomerization domain, leucine-rich

201 ceptor-interacting protein 1, IFNbeta-1, and nucleotide-binding oligomerization domain, leucine-rich

202 TRIF-related adapter molecule, IRF-3, HIF-1, nucleotide-binding oligomerization domain, leucine-rich

203 f the Crohn's disease susceptibility protein nucleotide-binding oligomerization domain-containing 2 (

204 muropeptides that more effectively activates nucleotide-binding oligomerization domain-containing pro

205 Nucleotide-binding oligomerization domain-containing pro

206 mal regulation of the innate immune receptor nucleotide-binding oligomerization domain-containing pro

207 nd synergistically enhanced by activation of nucleotide-binding oligomerization domain-containing pro

208 The nucleotide-binding oligomerization domain-containing pro

209 by C-C chemokine receptor (CCR) 2, CCR5, and nucleotide-binding oligomerization domain-containing pro

210 Mutations in nucleotide-binding oligomerization domain-containing pro

211 mune sensors, including Toll-like receptors, nucleotide-binding oligomerization domain-containing rec

212 including, cytokine and chemokine signaling, nucleotide-binding oligomerization domain-like receptor

213 Excessive nucleotide-binding oligomerization domain-like receptor

214 eta precursor requires processing by the the nucleotide-binding oligomerization domain-like receptor

215 n of bone marrow-derived macrophages via the nucleotide-binding oligomerization domain-like receptor

216 atory effects of the innate immune molecule, nucleotide-binding oligomerization domain-like receptors

217 bial sensors, recent evidence indicates that nucleotide-binding oligomerization domains (NODs) can al

218 his approach by investigating the effects of nucleotide binding on the structure of myosin's catalyti

219 kinase domain is repurposed for noncanonical nucleotide binding or to stabilize unique, inactive kina

220 ises DNA binding, conformational transition, nucleotide binding, phosphoester bond formation, and dis

221 art of the communication pathway between the nucleotide binding pocket (purine binding loop) and the

222 ghly conserved residues localized around the nucleotide binding pocket of the GTPase and are predicte

223 is able to adjust the key residues in the 5-nucleotide binding pocket to compensate for the change i

224 reported GPCR-G(i/o) complexes (in which the nucleotide-binding pocket adopts more flexible conformat

225 owed DNA ordered in the previously described nucleotide-binding pocket, supporting the suggested role

226 nities coordinated by residues in the GTPase nucleotide-binding pocket.

227 ve to the receptor and exhibits a more rigid nucleotide-binding pocket.

228 Three consecutive nucleotide-binding pockets are occupied by the GTP analo

229 Thus, the NTRs affect the specific nucleotide-binding properties of MYO1C isoforms, adding

230 Human guanine nucleotide binding protein like 1 (GNL1) is an evolution

231 Family B heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors

232 insights into the dynamic process of guanine nucleotide-binding protein (G-protein) activation.

233 ify that a cluster of five Immune-associated nucleotide-binding protein (IAN) genes (IAN2 to IAN6) is

234 This poses the question of how NBP35 (Nucleotide-Binding Protein 35 kDa), the heteromeric part

235 of protein kinase A (PRKACA) or the guanine nucleotide-binding protein subunit alpha (GNAS) gene, th

236 between beta3 integrin and Galpha13 (guanine nucleotide-binding protein subunit alpha 13), resulting

237 Floxed Des1 mice, on a guanine nucleotide-binding protein subunit alpha transducin 1 kn

238 we show by microarray and RNAi that guanine nucleotide-binding protein subunit alpha13 (Galpha13) is

239 Guanine nucleotide-binding proteins (G proteins) facilitate the

240 Heterotrimeric guanine nucleotide-binding proteins (G proteins), which are comp

241 inhibits signaling to heterotrimeric guanine nucleotide-binding proteins (G proteins).

242 structural and dynamic features that define nucleotide binding, providing insight into how altering

243 se that communication between the actin- and nucleotide-binding regions of myosin assures a proper ac

244 couples structural changes in the actin- and nucleotide-binding regions with force generation.

245 Upon nucleotide binding, RG then rewinds ~1 turn of DNA.

246 guished most sensitively by the two Walker A nucleotide-binding segments.

247 s, but the mechanisms that enable the cyclic nucleotide-binding signal to regulate distant domains ar

248 which depends on a conserved cysteine in its nucleotide binding site (C20).

249 etabolism is coordinated by three classes of nucleotide binding site (NBS).

250 ethionine residue M584 (Walker B sequence of nucleotide binding site 1) by glutamate imparted hydroly

251 hen the catalytic glutamate of the canonical nucleotide binding site 2 was mutated to glutamine.

252 ion with a citrate of crystallization at the nucleotide binding site and exhibits structural features

253 Nucleotide binding site leucine-rich repeat (NLR) protei

254 single gene candidate encoding a coiled-coil nucleotide binding site Leucine-rich repeat (NLR) recept

255 r extent, in the switch regions flanking the nucleotide binding site, can shed light on binding and a

256 The cytosolic nucleotide binding site-leucine rich repeat (NBS-LRR) re

257 Nucleotide binding site-leucine rich repeats (NLRs), rec

258 contains a zinc ion complex and a guanosine nucleotide binding site.

259 ding cassette proteins with one noncanonical nucleotide binding site.

260 ast and forms a distinct penultimate (n - 1) nucleotide binding site.

261 rived from WEW, which encodes a coiled-coil, nucleotide-binding site and leucine-rich repeat protein

262 in mouse liver, we show that proximity to a nucleotide-binding site increases the risk of N-acetylat

263 sp superfamily of enzymes shares an atypical nucleotide-binding site known as the ATP-grasp fold.

264 ogens by plants is mediated by intracellular nucleotide-binding site leucine-rich repeat (NLR) recept

265 The mapped genes included 639 nucleotide-binding site leucine-rich repeat genes (NBS-L

266 Nucleotide-binding site leucine-rich repeat resistance g

267 mutations disrupt communication between the nucleotide-binding site of myosin and its lever arm that

268 nsion of switch 1 away from the G-domain and nucleotide-binding site of the KRAS protein.

269 s) of the hGMPK CORE domain distant from the nucleotide-binding site of this domain modulate enzymati

270 essed by swapping it with the Sec7d from ARF nucleotide-binding site opener (ARNO)/cytohesin-2, a pla

271 er, a reciprocal signal, propagated from the nucleotide-binding site, provides a mechanism for coupli

272 f 1216 receptor kinases and 56% (343) of 616 nucleotide-binding site-leucine-rich repeat genes harbor

273 on and enable loop restructuring to form the nucleotide-binding site.

274 ine and guanine nucleotides to the canonical nucleotide binding sites of the regulatory Bateman domai

275 nother parasite protein with putative cyclic nucleotide binding sites, Plasmodium falciparum EPAC (Pf

276 nhibitors in favor of structurally symmetric nucleotide binding sites.

277 the regulatory RCK domains, thus connecting nucleotide-binding sites and ion gates.

278 sine N-acylation by acyl-CoAs is enhanced by nucleotide-binding sites and may contribute to higher st

279 act sites of the takinib scaffold within the nucleotide-binding sites of each respective kinase.

280 Additional nucleotide-binding sites were found on the face of the p

281 ro lysine N-malonylation by malonyl-CoA near nucleotide-binding sites which overlaps with in vivo N-a

282 P greatly diminish N-malonylation near their nucleotide-binding sites, but not at distant lysine resi

283 ate characterized by structurally asymmetric nucleotide-binding sites.

284 isentangles the protein conformation and the nucleotide binding state of Hsp90 and extracts the kinet

285 terodimeric Rag GTPases among four different nucleotide-binding states, only one of which (RagA/B*GTP

286 ve site in the absence of PPi, suggests that nucleotide binding stimulates PPi dissociation and occur

287 g resonance energy transfer (QRET) assay for nucleotide binding studies with RAS and heterotrimeric G

288 36-amino acid long C-terminal domain in the nucleotide-binding subunit alpha (Mtalpha) of F-ATP synt

289 Here, we employed the Gnb4 (guanine nucleotide-binding subunit beta-4) cre driver line in mi

290 ending, we have investigated the kinetics of nucleotide binding to axonemes.

291 protochlorophyllide reduction, illustrating nucleotide binding to both subunits as a prerequisite fo

292 domain that is essential for coupling cyclic nucleotide binding to channel opening.

293 cleotides) of steady-state and time-resolved nucleotide binding to dissect the role of NBS2 of the ac

294 simultaneously measured channel currents and nucleotide binding to Kir6.2.

295 a coli SMC complex, MukBEF, as a function of nucleotide binding to MukB and subsequent ATP hydrolysis

296 Mg-nucleotide binding to SUR1 stimulates K(ATP).

297 s conformational changes triggered by cyclic nucleotide binding to the gate.

298 ormation of HerA and detail the mechanism of nucleotide binding to the HerA-NurA complex from thermop

299 FliM interacts with FlhG independent of nucleotide binding, while FlrA exclusively interacts wit

300 Comparison of nucleotide-binding with ionic currents suggests a model